Immunic (IMUX) Profit After Tax (2013 - 2026)

Immunic has reported Profit After Tax for 14 years, with the latest figure at -$32.6 million in Q1 2026.

• Quarterly Profit After Tax fell 27.93% year-over-year to -$32.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$105.8 million (down 9.81% YoY) and the FY2025 annual result came in at -$98.7 million, up 1.77% from the prior year.
• Profit After Tax retreated to -$32.6 million in Q1 2026 per IMUX's latest filing, from -$20.9 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$20.8 million in Q1 2022 and troughed at -$56.5 million in Q4 2022.
• A 5-year average of -$26.2 million and a median of -$24.4 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax slumped 166.58% in 2022, then jumped 61.8% in 2023.
• Over 5 years, Profit After Tax stood at -$56.5 million in 2022, then surged by 61.8% to -$21.6 million in 2023, then decreased by 16.7% to -$25.2 million in 2024, then rose by 17.14% to -$20.9 million in 2025, then slumped by 56.21% to -$32.6 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$32.6 million, -$20.9 million, and -$25.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.